Date:	2021/3/9	
Your Name:	Tao Li	
Manuscript Title:	_ Anlotinib combined	with gefitinib can significantly improve the proliferation of epidermal growth
factor receptor-m	nutant advanced non-	small cell lung cancer in vitro and in vivo
Manuscript numb	oer (if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for	<b>X</b> None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	<b>X</b> None	
O	testimony	_ <b>^</b> None	
	testimon,		
7	Support for attending	<b>X</b> None	
	meetings and/or travel		
	•		
8	Patents planned, issued or	<b>X</b> None	
	pending		
9	Participation on a Data	<b>X</b> None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	_ <b>X</b> None	
	in other board, society, committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	<b>X</b> None	
	·		
12	Receipt of equipment,	<b>X</b> None	
	materials, drugs, medical		
	writing, gifts or other		
13	services Other financial or non-	V Name	
13	financial interests	<b>X</b> None	
	arrorar fireer coto		
Ple	ease summarize the above co	onflict of interest in the fol	lowing box:
			Ţ.

Date:	2021/3/9
Your Name:	Yuxian Qian
Manuscript Title:_	Anlotinib combined with gefitinib can significantly improve the proliferation of epidermal growtl
factor receptor-mu	ant advanced non-small cell lung cancer in vitro and in vivo
Manuscript number	(if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for	X _	_None	
	lectures, presentations,			
	speakers bureaus,			
	manuscript writing or educational events			
6	Payment for expert	Х	Nama	
0	testimony	^_	_None	
	testimony			
7	Support for attending	Y	None	
•	meetings and/or travel		_140110	
	Ç ,			
8	Patents planned, issued or	Х	None	
	pending		<del>_</del>	
9	Participation on a Data	x _	_None	
	Safety Monitoring Board or			
	Advisory Board			
10	Leadership or fiduciary role	_ X	_None	
	in other board, society, committee or advocacy			
	group, paid or unpaid			
11	Stock or stock options	Х	None	
	•			
12	Receipt of equipment,	x _	_None	
	materials, drugs, medical			
	writing, gifts or other			
12	services Other financial or non-		••	
13	financial interests	X_	_None	
	illialiciai liiterests			
Ple	ase summarize the above c	onflict	of interest in the fo	llowing box:

Date:	2021/3/9
Your Name:	Chen-Fei Zhang
Manuscript Title:_	Anlotinib combined with gefitinib can significantly improve the proliferation of epidermal growth
factor receptor-m	utant advanced non-small cell lung cancer in vitro and in vivo
Manuscript numb	er (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for	X _	_None	
	lectures, presentations,			
	speakers bureaus,			
	manuscript writing or educational events			
6	Payment for expert	Х	Nama	
0	testimony	^_	_None	
	testimony			
7	Support for attending	Y	None	
•	meetings and/or travel		_140110	
	•			
8	Patents planned, issued or	x	_None	
	pending			
9	Participation on a Data	X _	_None	
	Safety Monitoring Board or			
	Advisory Board			
10	Leadership or fiduciary role	_ X	_None	
	in other board, society, committee or advocacy			
	group, paid or unpaid			
11	Stock or stock options	Х	None	
12	Receipt of equipment,	x _	_None	
	materials, drugs, medical			
	writing, gifts or other			
13	services Other financial or non-	V	None	
13	financial interests	^_	None	
Ple	ase summarize the above c	onflict	of interest in the fo	llowing box:

Date:	_2021/3/9
Your Name:	Junji Uchino
Manuscript Title:_	Anlotinib combined with gefitinib can significantly improve the proliferation of epidermal growth
factor receptor-mu	tant advanced non-small cell lung cancer in vitro and in vivo
Manuscript numbe	r (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for	XNone
	lectures, presentations,	
	speakers bureaus,	
	manuscript writing or	
_	educational events	<b>.</b>
6	Payment for expert testimony	XNone
	testimony	
7	Support for attending	V. Nove
,	meetings and/or travel	<b>X</b> None
	meetings and, or traver	
8	Patents planned, issued or	X None
J	pending	^
	F 2002	
9	Participation on a Data	X None
	Safety Monitoring Board or	
	Advisory Board	
10	Leadership or fiduciary role	X None
	in other board, society,	
	committee or advocacy	
	group, paid or unpaid	
11	Stock or stock options	XNone
12	Possint of aguinment	V. Nove
12	Receipt of equipment, materials, drugs, medical	XNone
	writing, gifts or other	
	services	
13	Other financial or non-	XNone
	financial interests	
Ple	ease summarize the above co	onflict of interest in the following box:

Date:	_2021/3/9
Your Name:	Mariano Provencio
Manuscript Title:_	AnIotinib combined with gefitinib can significantly improve the proliferation of epidermal growth
factor receptor-m	utant advanced non-small cell lung cancer in vitro and in vivo
Manuscript number	er (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for	XNone
	lectures, presentations,	
	speakers bureaus,	
	manuscript writing or	
6	educational events Payment for expert	X None
ь	testimony	_ <b>X</b> None
	testimony	
7	Support for attending	X None
,	meetings and/or travel	^Notice
	meetings and, or traver	
8	Patents planned, issued or	X None
	pending	XNone
9	Participation on a Data	X None
	Safety Monitoring Board or	
	Advisory Board	
10	Leadership or fiduciary role	_ <b>X</b> None
	in other board, society,	
	committee or advocacy	
11	group, paid or unpaid	
11	Stock or stock options	XNone
12	Receipt of equipment,	X None
12	materials, drugs, medical	^None
	writing, gifts or other	
	services	
13	Other financial or non-	<b>X</b> None
	financial interests	
- וח	oco cummonino the charre	andlist of interest in the following boy.
Pie	ase summarize the above co	onflict of interest in the following box:

Date:	_2021/3/9
Your Name:	Yan Wang
Manuscript Title:_	Anlotinib combined with gefitinib can significantly improve the proliferation of epidermal growtl
factor receptor-mu	tant advanced non-small cell lung cancer in vitro and in vivo
Manuscript number	r (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for	<b>X</b> None	
	lectures, presentations,	<b>X</b> None	
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	<b>X</b> None	
	testimony		
7	Support for attending	<b>X</b> None	
	meetings and/or travel		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	<b>X</b> None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	_ <b>X</b> None	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	<b>X</b> None	
		XNone	
12	Receipt of equipment,	<b>X</b> None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	<b>X</b> None	
	financial interests		
Pla	ease summarize the above c	onflict of interest in the fo	llowing hox:
- 10	.asc sammanze the above t	ommet of interest in tile 10	nowing son.

Date:	2021/3/9
Your Name:	_ Xiang-Rong Shi
Manuscript Title:_ A	nlotinib combined with gefitinib can significantly improve the proliferation of epidermal growth
factor receptor-mut	ant advanced non-small cell lung cancer in vitro and in vivo
Manuscript number	(if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	_ XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	<b>X</b> None	
3	Royalties or licenses	<b>X</b> None	
4	Consulting fees	XNone	

5	Payment or honoraria for	<b>X</b> None			
	lectures, presentations,				
	speakers bureaus,				
	manuscript writing or				
-	educational events	V. Name			
6	Payment for expert testimony	_ <b>X</b> None			
	testimony				
7	Support for attending	X None			
,	meetings and/or travel	<b>X</b> None			
	meetings and, or traver				
8	Patents planned, issued or	<b>X</b> None			
	pending				
	. 0				
9	Participation on a Data	<b>X</b> None			
	Safety Monitoring Board or				
	Advisory Board				
10	Leadership or fiduciary role	_ <b>X</b> None			
	in other board, society,				
	committee or advocacy				
11	group, paid or unpaid	•			
11	Stock or stock options	XNone			
12	Receipt of equipment,	X None			
12	materials, drugs, medical	<b>X</b> None			
	writing, gifts or other				
	services				
13	Other financial or non-	<b>X</b> None			
	financial interests				
- ומ	Discontinuous de alegan conflict of interest in the fall and i				
PIE	Please summarize the above conflict of interest in the following box:				

Date:	_2021/3/9
Your Name:	Yan Zhang
Manuscript Title:_	AnIotinib combined with gefitinib can significantly improve the proliferation of epidermal growth
factor receptor-mu	utant advanced non-small cell lung cancer in vitro and in vivo
Manuscript number	er (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for	X Nor	ne	
	lectures, presentations,	^		
	speakers bureaus,			
	manuscript writing or			
	educational events			
6	Payment for expert	X Nor	ne	
	testimony	XNOI	TC .	
	,			
7	Support for attending	<b>X</b> Nor	20	
,	meetings and/or travel	<b>^</b> NOI	ie	
	meetings and/or traver			
8	Patents planned, issued or	<b>X</b> Nor	ne	
	pending			
9	Participation on a Data	<b>X</b> Nor	ne	
	Safety Monitoring Board or			
	Advisory Board			
10	Leadership or fiduciary role	noN X	ne	
	in other board, society,			
	committee or advocacy			
	group, paid or unpaid			
11	Stock or stock options	X Nor	ne	
12	Receipt of equipment,	X Nor	ne	
	materials, drugs, medical			
	writing, gifts or other			
	services			
13	Other financial or non-	X Nor	ne	
	financial interests			
Ple	ease summarize the above co	onflict of in	terest in the fo	llowing box:
L				

Date:	_2021/3/9			
Your Name:	Xiao-Dong Zhang			
Manuscript Title:_	Anlotinib combined with gefitinib can significantly improve the proliferation of epidermal growt			
factor receptor-mutant advanced non-small cell lung cancer in vitro and in vivo				
Manuscript number (if known):				

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
	Time frame: Since the initial planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	_ XNone		
	Time frame: past 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	<b>X</b> None		
3	Royalties or licenses	XNone		
4	Consulting fees	XNone		

5	Payment or honoraria for	X None			
	lectures, presentations,				
	speakers bureaus,				
	manuscript writing or				
	educational events				
6	Payment for expert	_ <b>X</b> None			
	testimony				
7	Support for attending	<b>X</b> None			
	meetings and/or travel				
8	Patents planned, issued or	X None			
	pending				
9	Participation on a Data	X None			
	Safety Monitoring Board or				
	Advisory Board				
10	Leadership or fiduciary role	X None			
	in other board, society,				
	committee or advocacy				
	group, paid or unpaid				
11	Stock or stock options	XNone			
12	Receipt of equipment,	XNone			
	materials, drugs, medical				
	writing, gifts or other				
13	services	V			
13	Other financial or non- financial interests	XNone			
	illialiciai liiterests				
Dla	Please summarize the above conflict of interest in the following box:				
ric	.a.se sammanize the above t	minet of interest in the following box.			